Miruvor
Sign up
The short answer

What studies of compression garments found

8papers on compression garments
16people in 1 study testing compression garments alone
1randomised trial, the strongest kind of study

At a glance, by condition

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, the randomised trial (very low certainty), for autonomic symptoms.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Compression garments might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 8 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Compression garments · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Autonomic symptoms1 study · 16 people took compression garments Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (16 in all).

The randomised trial18 randomised · 16 analysed · 15 min · 20–25 mm Hg compression, during tilt test

Autonomic symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of compression garments on autonomic symptoms in ME/CFS. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (16 in all)
See the 1 study
  1. Compression Stockings Improve Cardiac Output and Cerebral Blood Flow during Tilt Testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients: A Randomized Crossover Trial. (2021)

    People in the study
    18 randomised · 16 analysed
    Dose
    20–25 mm Hg compression, during tilt test
    Outcome
    CO upright (L/min)
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Studies of combinations

Outcomes that only studies of compression garments given together with other treatments looked at. Shown, not graded: they can’t tell what compression garments did alone.

Daily functioning Both together

Combination: Physical therapy / physiotherapy + Cycling + Jogging and running + Salt, electrolytes and fluids + Compression garments + Fludrocortisone / Florinef + Midodrine + Atenolol (Tenormin) + Mestinon / pyridostigmine + Ivabradine + Clonidine + Methylphenidate (Ritalin, Concerta) + Fexofenadine (Allegra) + Famotidine (Pepcid) + Cromolyn (Gastrocrom, Nalcrom) + Baicalein and quercetin + Escitalopram (Lexapro) + Low-dose naltrexone1 in the study

A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023): activity tolerance competing in cross country event, better (not tested).

Shown, not counted: compression garments was given together with other treatments.

Side effects

Stopping because of side effects1 study

All papers

  1. Compression Stockings Improve Cardiac Output and Cerebral Blood Flow during Tilt Testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients: A Randomized Crossover Trial.2021 · randomised trial · 18 randomised · 16 analysed
    Summary

    In a randomized crossover trial, 18 ME/CFS patients who consented to treatment with compression stockings for orthostatic intolerance symptoms were invited to participate; 16 were analysed. Each underwent two 15-min head-up tilt table tests, one with and one without knee-high compression stockings providing 20–25 mm Hg compression, in randomized order. The study measured heart rate and blood pressure, cardiac output using Doppler, and cerebral blood flow using extracranial Doppler of the internal carotid and vertebral arteries. There were no differences in heart rate and blood pressure at either end-tilt testing period. Compared with stockings off, upright cardiac output was 4.43 (0.94) L/min with stockings versus 4.01 (0.89) L/min without (p < 0.0001), and upright cerebral blood flow was 490 (456–551) mL versus 431 (400–473) mL (p < 0.0001). The mean percentage reduction in cardiac output during the test was lower with stockings, 15 (4)% versus 27 (6)% (p < 0.0001), as was the mean percentage cerebral blood flow reduction, 14 (4)% versus 25 (5)% (p < 0.0001). One patient was excluded because tilt testing without stockings could not be performed due to rapid onset of severe OI symptoms; another was excluded for insufficient image quality. The authors state that they studied a limited number of patients, which could have introduced an inclusion bias, and that it remains to be determined whether compression stockings are as effective during a prolonged period of standing compared to a short period of standing.

  2. Treatment of long COVID complicated by postural orthostatic tachycardia syndrome2023 · compared with another group · 34 started · 32 with outcome data · preprint
  3. Patient-reported treatment outcomes in ME/CFS and long COVID.2025 · no comparison group · 5,451 in the study · 3,925 with outcome data
  4. Treatment of long COVID complicated by postural orthostatic tachycardia syndrome-Case series research.2024 · no comparison group · 34 in the study · 32 started · 32 with outcome data
    Summary

    The authors aimed to describe the treatment course of long COVID complicated by POTS. At the outpatient clinic of St. Marianna University Hospital, 34 patients met POTS criteria; 32 were followed after excluding 2 who had only two visits because of hospital transfer. Median follow-up was 159 (IQR: 90.5–264.5) days. Treatment included counseling to consume ≥10 g of salt and 2–3 L of water, elastic compression stockings, and bisoprolol 0.625 to 2.5 mg once daily, with SSRIs, midodrine, rTMS, EAT, Chinese herbal medicine, or psychiatrist consultation in some cases. There was no comparison group. After 2 weeks to 1 month, 19 patients were aware of the effects of bisoprolol treatment and 13 were unaware. From initial to last visit, ΔHR improved from 38 (34–43.5) to 17.5 (13–28) and PS score from 4 (2–6) to 1 (0–2). Employment or study status “continued with the same job description or went to school” changed from 10 (31.3%) to 22 (68.8%), and “leave of absence or school leave” from 13 (40.6%) to 5 (15.6%). Harms were not reported. Authors state limitations: single-center descriptive study; patients referred from neighboring institutions.

  5. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.2023 · combination: given with other treatments · 1 in the study
    Summary

    This case study reports a 19-year-old male who developed impairment consistent with ME/CFS after SARS-CoV-2 infection. The study reports one patient; there was no comparison group, and outcomes were before-versus-after over 30 months. Treatment included physical therapy; stationary biking and running as graded activity; oral sodium chloride and lower limb compression garments; and medications/supplements: fludrocortisone, midodrine, atenolol, pyridostigmine bromide, ivabradine, clonidine, methylphenidate, fexofenadine, famotidine, cromolyn, quercetin, escitalopram, and naltrexone. The paper reports significant improvement in symptoms over 30 months. With cromolyn, peak walking heart rate fell from the 130–140 bpm range to 100–105 bpm. Stopping fexofenadine and famotidine was accompanied on more than one occasion by increased fatigue and cognitive dysfunction; stopping H1 and H2 antihistamines was associated with worsened concentration and short-term memory. Naltrexone was associated with improved energy and overall function, and the patient reported improvements with low doses of clonidine and methylphenidate. For the first 15 months after infection, he continued to have exercise intolerance, with heart rate reaching 130–150 bpm during each of two 15-min walks daily. At one year, remaining symptoms included daily fatigue; lightheadedness and headaches were infrequent. He later resumed running at 10 min four times a week, increased running by two minutes each week, and in October 2022 competed in an 8 K event. Adverse effects were reported with fludrocortisone, midodrine, atenolol, pyridostigmine bromide, and ivabradine. Limitations stated include possible spontaneous improvement and uncertainty about independent effects of interventions.

  6. Orthostatic and Exercise Intolerance in Recreational and Competitive Athletes With Long COVID.2022 · combination: given with other treatments · 3 in the study
    Summary

    This case series described 3 recreational and competitive athletes with post-acute sequelae of SARS-CoV-2 infection (PASC) and orthostatic or exercise intolerance; one also met criteria for POTS. Patient 1, a 31-year-old female recreational alpine skier, received compression stockings, an aggressive increase in fluid and sodium intake, and a structured graduated exercise regimen emphasizing recumbent exercises and strength training, with rowing as cardiovascular exercise, over 4 months. Her symptoms steadily improved, and at follow-up she felt ready to attempt skiing again. Patient 2, an 18-year-old male collegiate rower, was started on pyridostigmine and a rehabilitation program focused on supine exercise. Patient 3, a 38-year-old woman, followed a modified PASC exercise program on a rowing machine, from week 1 at 5 min/d 5 times/wk to week 12 at 27 min/d 5 times/wk. By week 28 of pregnancy her PASC symptoms were improved, although she had not completely recovered; by the end of pregnancy her PASC symptoms resolved. There was no comparison group, no randomisation and no blinding; harms were not reported. The authors caution that exercise recommendations should be given cautiously to patients with post-exertional malaise.

  7. Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
    Summary

    This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime